SCHEMBL29492205

SCHEMBL29492205

CCOC(=O)Cc1nn(C(C)C)c2cc(C(F)(F)F)ccc2c1=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ RECQL P46063 1/20 0.39
▸ HTR2A P28223 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ GRIN1 Q05586 2/20 0.37
▸ GRIN2B Q13224 2/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ AKR1B1 P15121 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ ALOX5 P09917 1/20 0.36
▸ DHFR P00374 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ PPARG P37231 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29492084 0.86 POLB (0.48) NLRP3AKR1B1POLB
SCHEMBL25431544 0.84 NLRP3 (0.59) NLRP3SMN1; SMN2RECQLALDH1A1POLB
SCHEMBL26979557 0.79 ADORA1 (0.45) ALOX5
SCHEMBL25357509 0.78 NLRP3 (0.38) NLRP3AKR1B1
SCHEMBL25429842 0.78 RECQL (0.50) SMN1; SMN2RECQLHTR2AHTR2CSLC6A4
SCHEMBL25357321 0.76 NLRP3 (0.53) NLRP3AKR1B1POLB
SCHEMBL29492112 0.76 NLRP3 (0.53) NLRP3AKR1B1POLB
SCHEMBL25359650 0.75 NLRP3 (0.51) NLRP3AKR1B1KMT2A
SCHEMBL25356354 0.73 NLRP3 (0.64) NLRP3SMN1; SMN2POLBRXFP1
SCHEMBL26980324 0.71 RBP4 (0.44) ALDH1A1POLBKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217346-B1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2025-07-02 — — EP disclosed
US-20230391756-A1 NEW COMPOUND JANSSEN PHARMACEUTICA NV (BE) 2023-12-07 — — US disclosed
EP-4217346-A1 NEW COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
WO-2022063876-A1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 — — WO disclosed
EP-3974415-A1 NLRP3 MODULATORS Janssen Pharmaceutica NV (BE) 2022-03-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391756-A1 NEW COMPOUND NLRP3, NLRP1, IL1R1 NLRP3 1/4885SMN1; SMN2 4695/4885RECQL 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback